Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
118.87
+3.44 (2.98%)
Sep 10, 2026, 2:26 PM EDT - Market open
Kymera Therapeutics Stock Forecast
Stock Price Forecast
According to 23 analysts polled by S&P Global, Kymera Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $134.71. The average 1-year stock price forecast is 13.33% higher than the current stock price, while the lowest is $111 (-6.62%) and the highest is $170 (+43.01%).
Price Target: $134.71 (+13.33%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Kymera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 17 | 18 | 17 | 17 | 17 |
| Buy | 5 | 5 | 5 | 5 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 23 | 24 | 23 | 24 | 24 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy Upgrades $180 | Buy | Upgrades | $180 | +51.43% | Sep 10, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $121 → $140 | Buy | Maintains | $121 → $140 | +17.78% | Sep 4, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $112 | Hold | Maintains | $112 | -5.78% | Sep 2, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $135 → $170 | Buy | Reiterates | $135 → $170 | +43.01% | Aug 31, 2026 |
| Wells Fargo | Wells Fargo | Buy Reiterates $116 → $151 | Buy | Reiterates | $116 → $151 | +27.03% | Aug 27, 2026 |
Financial Forecast
Revenue This Year
105.30M
from 39.21M
Increased by 168.55%
Revenue Next Year
44.16M
from 105.30M
Decreased by -58.06%
EPS This Year
-3.81
from -3.69
EPS Next Year
-4.95
from -3.81
EPS and Forward PE are based on non-GAAP adjusted numbers.